3 May 2017

The nonprofit International Partnership for Microbicides (IPM) announced today the start of the first clinical trial of its three-month vaginal ring designed to prevent two of the greatest risks to women’s health: HIV, which disproportionately strikes women of reproductive age, and unintended pregnancy, a leading contributor to maternal mortality. The three-month vaginal ring is designed to slowly — and simultaneously — release the antiretroviral drug dapivirine to prevent HIV and the contraceptive hormone levonorgestrel.

Read the full article online here.